Efficacy of Tranexamic Acid in Hemoptysis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02781597|
Recruitment Status : Completed
First Posted : May 24, 2016
Last Update Posted : May 24, 2016
|Condition or disease||Intervention/treatment||Phase|
|Hemoptysis||Drug: Tranexamic Acid Drug: Placebo||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||66 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Efficacy of Tranexamic Acid in Controlling Hemoptysis, A Randomized Control Trial|
|Study Start Date :||January 2011|
|Actual Primary Completion Date :||June 2012|
|Actual Study Completion Date :||June 2012|
Active Comparator: Tranexamic acid
All patients will receive basic resuscitative measures and standard treatment like assessment and management of Airway, breathing, circulation, antitussives, and blood products. Patients in group T will receive Inj Tranexamic acid in a loading dose of 1 g over 10 min followed by an infusion of 1 g over 8 h.
Drug: Tranexamic Acid
Patients will receive Inj Tranexamic acid, in IV in a loading dose of 1 g over 10 min followed by an infusion of 1 g over 8 h in 500ml normal saline
Other Name: TA
Placebo Comparator: Placebo
All patients will receive basic resuscitative measures and standard treatment like assessment and management of Airway, breathing, circulation, antitussives, and blood products. Patients will receive 0.9% normal saline instead of Tranexamic acid.
Patients will receive 0.9% normal saline
Other Name: Placebo control
- Change in severity of hemoptysis [ Time Frame: day1 and day2 ]Frequency, amount, VAS score Objective assessment using VAS score at admission and at 48 hours.
- Intervention needed [ Time Frame: 2 days ]Whether intervention needed to control hemoptysis, in the form of bronchial/pulmonary artery embolization or surgery.(Yes/No)
- Blood transfusion needed [ Time Frame: 2 days ]Number of blood transfused
- Hospital stay [ Time Frame: Through study completion, an average of 1 year ]Number of days of hospital stay
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02781597
|Post graduate institute of medical education and research|
|Chandigarh, UT, India, 160012|